IS4637A - Ónæmislyf byggð á efnum sem bindast CB2-viðtaka - Google Patents
Ónæmislyf byggð á efnum sem bindast CB2-viðtakaInfo
- Publication number
- IS4637A IS4637A IS4637A IS4637A IS4637A IS 4637 A IS4637 A IS 4637A IS 4637 A IS4637 A IS 4637A IS 4637 A IS4637 A IS 4637A IS 4637 A IS4637 A IS 4637A
- Authority
- IS
- Iceland
- Prior art keywords
- group
- alkyl
- hydrogen
- halogen
- atom
- Prior art date
Links
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 title 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
- -1 1,2,3,4-tetrahydronaphth-1-yl Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000003367 polycyclic group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 abstract 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004534 benzothien-2-yl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004197 benzothien-3-yl group Chemical group [H]C1=C(*)C2=C([H])C([H])=C([H])C([H])=C2S1 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 102000056693 human CNR2 Human genes 0.000 abstract 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 abstract 1
- 229940124622 immune-modulator drug Drugs 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9507438A FR2735774B1 (fr) | 1995-06-21 | 1995-06-21 | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| PCT/FR1996/000959 WO1997000860A1 (fr) | 1995-06-21 | 1996-06-20 | Composes agonistes du recepteur cb¿2? |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS4637A true IS4637A (is) | 1997-12-19 |
Family
ID=9480236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS4637A IS4637A (is) | 1995-06-21 | 1997-12-19 | Ónæmislyf byggð á efnum sem bindast CB2-viðtaka |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6013648A (is) |
| EP (1) | EP0833818B1 (is) |
| JP (1) | JP3417566B2 (is) |
| KR (1) | KR19990028272A (is) |
| CN (1) | CN1150166C (is) |
| AT (1) | ATE207054T1 (is) |
| AU (1) | AU717858B2 (is) |
| BR (1) | BR9608640A (is) |
| CA (1) | CA2225379A1 (is) |
| CZ (1) | CZ292630B6 (is) |
| DE (1) | DE69616056T2 (is) |
| DK (1) | DK0833818T3 (is) |
| EE (1) | EE9700345A (is) |
| ES (1) | ES2165986T3 (is) |
| FR (1) | FR2735774B1 (is) |
| HU (1) | HUP9900019A3 (is) |
| IL (1) | IL122637A0 (is) |
| IS (1) | IS4637A (is) |
| MX (1) | MX9710251A (is) |
| NO (1) | NO975989L (is) |
| NZ (1) | NZ312161A (is) |
| PL (1) | PL185598B1 (is) |
| PT (1) | PT833818E (is) |
| RU (1) | RU2200736C2 (is) |
| SI (1) | SI0833818T1 (is) |
| SK (1) | SK283660B6 (is) |
| TR (1) | TR199701660T1 (is) |
| UA (1) | UA67717C2 (is) |
| WO (1) | WO1997000860A1 (is) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| WO1999057107A2 (en) * | 1998-05-04 | 1999-11-11 | The University Of Connecticut | Cannabinoids selective for the cb2 receptor |
| EP1075470B1 (en) | 1998-05-04 | 2003-08-13 | The University Of Connecticut | Novel analgesic and immunomodulatory cannabinoids |
| US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US7589220B2 (en) | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
| DE19837627A1 (de) * | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
| US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| GB9923314D0 (en) * | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
| EP1702617A1 (en) * | 1999-10-18 | 2006-09-20 | The University Of Connecticut | Cannabimimetic indole derivatives |
| WO2001028329A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Peripheral cannabinoid receptor (cb2) selective ligands |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US8084467B2 (en) | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US6943266B1 (en) | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
| US6900236B1 (en) | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
| MXPA02005101A (es) * | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de indol canabimimeticos. |
| US7741365B2 (en) | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
| IL132661A (en) * | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
| CA2399791A1 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| JP2003534298A (ja) * | 2000-05-23 | 2003-11-18 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 咳の新規治療法 |
| JP2004513076A (ja) | 2000-07-25 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療で有用なｎ−置換インドール類 |
| US6541510B2 (en) * | 2000-09-28 | 2003-04-01 | Immugen Pharmaceuticals, Inc. | Antiviral methods and compounds |
| AU2001296402A1 (en) * | 2000-09-28 | 2002-04-08 | Immugen Pharmaceuticals, Inc. | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| AUPR118000A0 (en) * | 2000-11-02 | 2000-11-23 | Amrad Operations Pty. Limited | Therapeutic molecules and methods |
| FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| US7329651B2 (en) | 2001-01-26 | 2008-02-12 | University Of Connecticut | Cannabimimetic ligands |
| ATE478670T1 (de) | 2001-01-29 | 2010-09-15 | Univ Connecticut | Rezeptor-selektive cannabimimetische aminoalkylindole |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| EP1414775B1 (en) | 2001-07-13 | 2012-12-19 | The University of Connecticut | Bicyclic cannabinoid |
| WO2003007901A1 (en) * | 2001-07-18 | 2003-01-30 | Unilever Plc | Hair and/or scalp treatment compositions |
| CA2464333C (en) | 2001-10-26 | 2011-07-26 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| HUP0401924A3 (en) * | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
| TW200407110A (en) * | 2001-11-23 | 2004-05-16 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
| CA2468794A1 (en) * | 2001-12-07 | 2003-06-19 | Virginia Commonwealth University | Treatment of neoplasia |
| US7528165B2 (en) * | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| US6933316B2 (en) * | 2001-12-13 | 2005-08-23 | National Health Research Institutes | Indole compounds |
| US7632955B2 (en) * | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
| WO2003061699A1 (en) * | 2001-12-27 | 2003-07-31 | Japan Tobacco, Inc. | Remedies for allergic diseases |
| US20040171613A1 (en) * | 2001-12-27 | 2004-09-02 | Japan Tobacco Inc. | Therapeutic agent for non-immediate type allergic diseases |
| ATE340792T1 (de) | 2002-02-01 | 2006-10-15 | Hoffmann La Roche | Substituierte indole als alpha-1 agonisten |
| DE60329981D1 (de) | 2002-02-19 | 2009-12-24 | Shionogi & Co | Antipruriginosa |
| CA2478338A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US20030232101A1 (en) * | 2002-03-18 | 2003-12-18 | Immugen Pharmaceuticals, Inc. | Topical formulations of resorcinols and cannibinoids and methods of use |
| FR2839718B1 (fr) * | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| US7217732B2 (en) * | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
| WO2004017922A2 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
| CA2506895A1 (en) | 2002-11-25 | 2004-06-10 | Schering Corporation | Cannabinoid receptor ligands |
| AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
| EP1644335A4 (en) | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| IL160420A0 (en) | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
| ATE444066T1 (de) * | 2004-06-22 | 2009-10-15 | Schering Corp | Liganden für den cannabinoidrezeptoren |
| US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| US7560481B2 (en) | 2004-12-21 | 2009-07-14 | Abbott Laboratories | Indoles are cannabinoid receptor ligands |
| US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| FR2893615B1 (fr) | 2005-11-18 | 2008-03-07 | Sanofi Aventis Sa | Derives de 3-acylindole, leur preparation et leur application en therapeutique |
| EP2024349B1 (en) | 2006-05-31 | 2017-08-02 | AbbVie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| CA2681586A1 (en) | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
| US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| MX2009012374A (es) | 2007-05-18 | 2009-12-01 | Abbott Lab | Compuestos novedosos como ligandos del receptor de canabinoides. |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| FR2933697B1 (fr) | 2008-07-11 | 2010-08-13 | Sanofi Aventis | Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique |
| US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| RU2011115087A (ru) | 2008-09-16 | 2012-10-27 | Эбботт Лэборетриз (Us) | Замещенные бензамиды в качестве лигандов каннабиноидного рецептора |
| PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
| US20120277296A1 (en) | 2009-07-23 | 2012-11-01 | Sophie Lotersztajn | Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease |
| FR2950055A1 (fr) | 2009-09-17 | 2011-03-18 | Sanofi Aventis | Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique |
| WO2012024670A2 (en) * | 2010-08-20 | 2012-02-23 | University Of Washington Through Its Center For Commercialization | Composition and methods for treating glioblastoma |
| JP5918264B2 (ja) | 2010-12-22 | 2016-05-18 | アッヴィ・インコーポレイテッド | Ｃ型肝炎阻害剤およびその使用 |
| FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
| US9416103B2 (en) * | 2012-01-09 | 2016-08-16 | The Board Of Trustees Of The University Of Arkansas | Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases |
| US9656981B2 (en) | 2012-07-20 | 2017-05-23 | The Regents Of The University Of California | Peripherally-acting cannabinoid receptor agonists for chronic pain |
| KR20150102511A (ko) * | 2014-02-28 | 2015-09-07 | 주식회사 아세아텍 | 베일러용 드로우 |
| CZ2014985A3 (cs) * | 2014-12-31 | 2016-03-09 | Vysoká škola chemicko- technologická v Praze | Derivát syntetického kanabinoidu, způsob jeho přípravy a použití |
| CZ306547B6 (cs) * | 2014-12-31 | 2017-03-01 | Vysoká škola chemicko - technologická v Praze | Derivát syntetického kanabinoidu, způsob jeho přípravy a použití |
| US20190133995A1 (en) * | 2016-04-29 | 2019-05-09 | Corbus Pharmaceuticals, Inc. | Methods for the treatment of infection |
| CN108794379A (zh) * | 2017-04-26 | 2018-11-13 | 华东师范大学 | 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用 |
| WO2019144126A1 (en) | 2018-01-22 | 2019-07-25 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| JP2023512821A (ja) | 2020-02-04 | 2023-03-29 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO77049A2 (ro) * | 1980-08-08 | 1981-06-22 | Institutul De Cercetari Chimico-Farmaceutice,Ro | Derivati de 2-metil-3-etilindol si procedeu de preparare a acestora |
| RO90049A2 (ro) * | 1984-12-25 | 1986-08-30 | Centrala Industriala De Medicamente Cosmetice,Coloranti Si Lacuri,Ro | Procedeu de preparare a clorhidratului hidrat de 1-(p-clorbenzoil)3-/2-(di-n-propilamino) etil/5-metoxi-2-metilindol |
| US5068234A (en) * | 1990-02-26 | 1991-11-26 | Sterling Drug Inc. | 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles |
| US5081122A (en) * | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5013837A (en) * | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US4973587A (en) * | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
-
1995
- 1995-06-21 FR FR9507438A patent/FR2735774B1/fr not_active Expired - Fee Related
-
1996
- 1996-06-20 CN CNB961961260A patent/CN1150166C/zh not_active Expired - Fee Related
- 1996-06-20 AT AT96922962T patent/ATE207054T1/de not_active IP Right Cessation
- 1996-06-20 DE DE69616056T patent/DE69616056T2/de not_active Expired - Fee Related
- 1996-06-20 TR TR97/01660T patent/TR199701660T1/xx unknown
- 1996-06-20 EE EE9700345A patent/EE9700345A/xx unknown
- 1996-06-20 AU AU63632/96A patent/AU717858B2/en not_active Ceased
- 1996-06-20 WO PCT/FR1996/000959 patent/WO1997000860A1/fr not_active Ceased
- 1996-06-20 RU RU98101097/14A patent/RU2200736C2/ru not_active IP Right Cessation
- 1996-06-20 PL PL96324185A patent/PL185598B1/pl not_active IP Right Cessation
- 1996-06-20 CA CA002225379A patent/CA2225379A1/en not_active Abandoned
- 1996-06-20 NZ NZ312161A patent/NZ312161A/xx unknown
- 1996-06-20 JP JP50362997A patent/JP3417566B2/ja not_active Expired - Fee Related
- 1996-06-20 SI SI9630401T patent/SI0833818T1/xx unknown
- 1996-06-20 IL IL12263796A patent/IL122637A0/xx not_active IP Right Cessation
- 1996-06-20 HU HU9900019A patent/HUP9900019A3/hu unknown
- 1996-06-20 PT PT96922962T patent/PT833818E/pt unknown
- 1996-06-20 ES ES96922962T patent/ES2165986T3/es not_active Expired - Lifetime
- 1996-06-20 SK SK1735-97A patent/SK283660B6/sk unknown
- 1996-06-20 BR BR9608640A patent/BR9608640A/pt not_active Application Discontinuation
- 1996-06-20 DK DK96922962T patent/DK0833818T3/da active
- 1996-06-20 KR KR1019970709586A patent/KR19990028272A/ko not_active Abandoned
- 1996-06-20 MX MX9710251A patent/MX9710251A/es not_active IP Right Cessation
- 1996-06-20 CZ CZ19974143A patent/CZ292630B6/cs not_active IP Right Cessation
- 1996-06-20 EP EP96922962A patent/EP0833818B1/fr not_active Expired - Lifetime
- 1996-06-20 UA UA97126177A patent/UA67717C2/uk unknown
-
1997
- 1997-12-19 IS IS4637A patent/IS4637A/is unknown
- 1997-12-19 NO NO975989A patent/NO975989L/no not_active Application Discontinuation
- 1997-12-22 US US08/995,902 patent/US6013648A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS4637A (is) | Ónæmislyf byggð á efnum sem bindast CB2-viðtaka | |
| NO982330L (no) | Pyrazolderivater, fremgangsmÕte for fremstilling derav og farmas°ytiske preparater inneholdende nevnte derivater | |
| HUP9802866A2 (hu) | 2,4,5-Triszubsztituált-fenil-keto-enol-származékok, intermedierjeik, a vegyületeket hatóanyagként tartalmazó inszekticid, akaricid és herbicid készítmények, valamint eljárás a vegyületek és készítmények előállítására és alkalmazására | |
| HUP9601285A2 (hu) | Szubsztituált N-(indol-2-karbonil)-béta-alanin-amidok és származékaik, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| DE69613240D1 (de) | N-aminoalkylfluorencarboxamide, neue klasse von dopaminerezeptor subtype spezifische liganden | |
| ATE194836T1 (de) | Benzimidazolverbindungen und ihre verwendung als modulatoren des gabaa-rezeptorkomplexes | |
| YU46787B (sh) | Derivati heteroaril 3-okso-propan-nitrila i postupak za njihovo dobijanje | |
| DE69412016D1 (de) | Substituierte arylalkoxybenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel | |
| IE862630L (en) | 3-VINYL AND 3-ETHYNYL-ß-CARBOLINES | |
| DK0669318T3 (da) | Alkoxymethylering af pyrroler til fremstilling af pesticider | |
| NO901083D0 (no) | Fremgangsmaate for fremstilling av nye 1,7-kondenserte 1h-indol-2-carboxylsyre-n-(1,4-benzodiazepin)-3-yl)amider. | |
| IL100212A (en) | Pyrroline compounds, a process for their preparation, their use to prepare pyrrole products and pyrrole products made by said process | |
| ATE261956T1 (de) | Thiophen- und benzothiophenderivate, deren verwendung und sie enthaltende zubereitung | |
| HUP9802407A1 (hu) | Eljárás kamptotecinszármazékok előállítására, valamint a közbenső termékként szolgáló vegyületek | |
| DE69402935D1 (de) | Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel | |
| ATE229509T1 (de) | Azacyclooktan- und heptan-derivate, ihre herstellung und ihre therapeutische verwendung | |
| AU2001233838A1 (en) | Benzofuran carboxamides and their therapeutic use | |
| ES428346A1 (es) | Procedimiento para preparar un ester fosforico derivado de la pirazolina. | |
| WO2000008020A8 (en) | Tricyclic carboxamides | |
| HUP9900895A2 (hu) | Simaizom sejtburjánzást gátló 2-szubsztituált benzimidazolszármazékok | |
| ES456041A1 (es) | Procedimiento de preparacion de nuevos derivados de ditiepi-no (1,4) (2,3-c) pirrol. | |
| HUP9901139A2 (hu) | Melatonin agonisták alkalmazása jóindulatú prosztata hiperplázia kezelésére alkalmas gyógyászati készítmények előállítására | |
| IL107915A (en) | N-substituted azabicycloheptane derivatives and their use as medicaments |